Reversal of Remimazolam by a Single Dose of Flumazenil

• Status: Not yet recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

Remimazolam, a brand-new sedative which has benzodiazepine property. It is an ultra-short acting sedative and regarded as a proper drug for procedural sedation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Konkuk University Medical Center
• Treatments: Flumazenil

Criteria

Inclusion Criteria:

• participants aged over 20 years scheduled for ambulatory gynecologic surgery.

Exclusion Criteria:

• allergy or hypersensitivity to flumazenil, benzodiazepines, NSAIDs, 5-HT3

• arrhythmia, myocardial infarction, coronary artery disease

• obstructive sleep apnea

• severe or acute respiratory distress

• tricyclic anti-depressant

• lactose intolerance

• BMI over 30kg/m2

• ASA classification 4 or 5